Scott Haden Kollins
Adjunct Professor in the Department of Psychiatry and Behavioral Sciences
Scott H. Kollins, PhD received his undergraduate degree in psychology from Duke and his Master’s and Doctorate degrees in Clinical Psychology from Auburn University. After completing his clinical internship at the University of Mississippi Medical Center, where he served as Chief Intern, he joined the faculty of the Department of Psychology at Western Michigan University for three years, before joining the Duke faculty in 2000. Dr. Kollins has published more than 125 scientific papers in peer-reviewed journals. Over the past 10 years, his research has been supported by 6 different federal agencies, including NICHD, NIDA, NIMH, NIEHS, NINDS, and EPA, and he currently holds a mid-career K24 award from NIDA. He has also served as PI on more than 40 industry-funded clinical trials and is a consultant to a number of pharmaceutical companies in the area of ADHD clinical psychopharmacology. He has served as a standing member of the Child Psychopathology and Developmental Disabilities study section and also served as an ad-hoc reviewer for 10 additional NIH study sections and 7 international granting agencies. He is an Associate Editor for the Journal of Attention Disorders and has reviewed for more than 50 different peer-reviewed journals. He is an elected member of the College on Problems of Drug Dependence and the American College of Neuropsychopharmacology. Dr. Kollins is a licensed clinical psychologist and maintains a practice through the ADHD Program’s outpatient clinic. His research interests are in the areas of psychopharmacology and the intersection of ADHD and substance abuse, particularly cigarette smoking.
A 6-week, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Efficacy and Safety Study of Dasotraline versus Placebo in Subjects 6 to 12 Years of Age with Attention Deficit Hyperactivity Disorder (ADHD) awarded by Sunovion Pharmaceuticals, Inc (Principal Investigator). 2015 to 2017
A Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Efficacy and Safety Study of 2 Doses of Dasotraline in Adults with Attention Deficit Hyperactivity Disorder (ADHD) awarded by Sunovion Pharmaceuticals, Inc (Principal Investigator). 2015 to 2017
A Ph. 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety & Efficacy of Evening-dosed HLD200, a Novel Delayed & ER Formulation (DELEXIS) of Methylphenidate Hydrochloride, on Post waking, Early Mor awarded by Ironshore Pharmaceuticals & Development, Inc (Principal Investigator). 2015 to 2016
An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD) awarded by Sunovion Pharmaceuticals, Inc (Principal Investigator). 2015 to 2016
SEP-225289 in Adults with Attention Deficit Hyperactivity Disorder (ADHD) awarded by Sunovion Pharmaceuticals, Inc (Principal Investigator). 2014 to 2016
A Phase IIb, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Crossover, Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults with Attention-Deficit Hyperactivity Disorder (ADHD) awarded by Neurovance (Principal Investigator). 2015 to 2016
A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of AR11 (Amphetamine Sulfate) in Pediatric Patients (Ages 6-12) with ADHD in a Laboratory Classroom awarded by Arbor Pharmaceuticals, Inc (Principal Investigator). 2013 to 2015
A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Evaluation of Single Oral Doses of SEP-225289 in Subjects 6 to 17 Years of Age with Attention Deficit Hyperactivity Disorder awarded by Sunovion Pharmaceuticals, Inc (Principal Investigator). 2015
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-ARM, MULTI-CENTER STUDY MEASURING THE EFFICACY AND SAFETY OF PRC-063 IN ADOLESCENT ADHD PATIENTS awarded by Purdue Pharma L.P. (Principal Investigator). 2014 to 2015
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-ARM, MULTI-CENTER STUDY MEASURING THE EFFICACY AND SAFETY OF PRC-063 IN ADULT ADHD PATIENTS awarded by Purdue Pharma L.P. (Principal Investigator). 2014 to 2015
Friis-Healy, Elsa A., et al. “It Is Time to REACT: Opportunities for Digital Mental Health Apps to Reduce Mental Health Disparities in Racially and Ethnically Minoritized Groups.” Jmir Ment Health, vol. 8, no. 1, Jan. 2021, p. e25456. Pubmed, doi:10.2196/25456. Full Text
Mitchell, John T., et al. “Sluggish cognitive tempo (SCT) in an adult outpatient sample seeking an attention-deficit/hyperactivity disorder assessment: Age of onset and assessment method impact on SCT rates.” J Psychiatr Res, vol. 131, Dec. 2020, pp. 203–08. Pubmed, doi:10.1016/j.jpsychires.2020.09.013. Full Text
Engelhard, Matthew M., et al. “Health system utilization before age 1 among children later diagnosed with autism or ADHD.” Sci Rep, vol. 10, no. 1, Oct. 2020, p. 17677. Pubmed, doi:10.1038/s41598-020-74458-2. Full Text
Adjei, Akwete L., et al. “A Pharmacokinetic Study of Methylphenidate Hydrochloride Multilayer Extended-Release Capsules (Aptensio XR®) in Preschool-Aged Children with Attention-Deficit/Hyperactivity Disorder.” Paediatr Drugs, vol. 22, no. 5, Oct. 2020, pp. 561–70. Pubmed, doi:10.1007/s40272-020-00409-z. Full Text
Lunsford-Avery, Jessica R., et al. “Feasibility and Acceptability of Wearable Sleep Electroencephalogram Device Use in Adolescents: Observational Study.” Jmir Mhealth Uhealth, vol. 8, no. 10, Oct. 2020, p. e20590. Pubmed, doi:10.2196/20590. Full Text
Fuemmeler, Bernard F., et al. “Associations between attention deficit hyperactivity disorder symptoms and eating behaviors in early childhood.” Pediatr Obes, vol. 15, no. 7, July 2020, p. e12631. Pubmed, doi:10.1111/ijpo.12631. Full Text
Childress, Ann C., et al. “Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder.” J Child Adolesc Psychopharmacol, vol. 30, no. 3, Apr. 2020, pp. 128–36. Pubmed, doi:10.1089/cap.2019.0117. Full Text
Kollins, Scott H., et al. “Increased subjective and reinforcing effects of initial nicotine exposure in young adults with attention deficit hyperactivity disorder (ADHD) compared to matched peers: results from an experimental model of first-time tobacco use.” Neuropsychopharmacology, vol. 45, no. 5, Apr. 2020, pp. 851–56. Pubmed, doi:10.1038/s41386-019-0581-7. Full Text
Kollins, Scott H., et al. “A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial.” Lancet Digit Health, vol. 2, no. 4, Apr. 2020, pp. e168–78. Pubmed, doi:10.1016/S2589-7500(20)30017-0. Full Text
Childress, Ann C., et al. “Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Preschool Children with Attention-Deficit/Hyperactivity Disorder.” J Child Adolesc Psychopharmacol, vol. 30, no. 2, Mar. 2020, pp. 58–68. Pubmed, doi:10.1089/cap.2019.0085. Full Text
Witt, K. L., et al. “Chromosomal aberrations, sister chromatid exchanges, and micronuclei in lymphocytes of pediatric ADHD patients treated with stimulant drugs.” Environmental and Molecular Mutagenesis, vol. 49, no. 7, WILEY-BLACKWELL, 2008, pp. 528–528.
Goodman, D., et al. “Efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.” International Journal of Neuropsychopharmacology, vol. 11, CAMBRIDGE UNIV PRESS, 2008, pp. 292–93.
Kollins, Scott H., et al. “Cognitive and sedative effects of guanfacine extended release in children and adolescents aged 6 to 17 years with attention-deficit/hyperactivity disorder: Safety and sleep effects.” Biological Psychiatry, vol. 63, no. 7, ELSEVIER SCIENCE INC, 2008, pp. 246S-246S.
Kollins, Scott, et al. “Genetic associations with reaction time variability in AD/HD.” American Journal of Medical Genetics Part B Neuropsychiatric Genetics, vol. 141B, no. 7, WILEY-LISS, 2006, pp. 771–72.
Schug, M. D., et al. “The genetics of AD/HD: Subtyping, comorbidity and developmental considerations.” American Journal of Medical Genetics Part B Neuropsychiatric Genetics, vol. 130B, no. 1, WILEY-LISS, 2004, pp. 103–103.